The recent failure of active immunotherapies targeting beta-amyloid in Alzheimer’s disease has dampened some of the initial enthusiasm for this approach. Development of AN1792, an active beta-amyloid vaccine, was terminated following the development of meningoencephalitis in 6% of vaccinated subjects. This complication was attributed to use of full-length beta-amyloid1-42. Read More
Latest News
NeuroSound Radio at ACTRIMS/ECTRIMS 2014 – Part 2
November 19, 2014NeuroSound Radio at ACTRIMS/ECTRIMS 2014 – Part 1
November 5, 2014Dr. Marcelo Kremenchutzky, Director of the MS Clinic in London, Ontario, interviews researchers and clinicians at MSBoston 2014, the joint meeting of the Americas and European Committee for Treatment and Research in MS (ACTRIMS/ECTRIMS). Read More
Toward a new standard in MS disease control
October 22, 2014REVIEWER: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada
Redefining therapeutic efficacy
Conclusions
New data on novel and emerging therapies were the centrepiece of the 2014 joint meeting of the Americas and European Committee for Research and Treatment of Multiple Sclerosis (ACTRIMS/ECTRIMS), with results suggesting that clinical standards are being redefined for optimal disease control in relapsing-remitting multiple sclerosis (RRMS). Read More